Stockscreener 앱 받기
2.16
0.23%
-0.005
전일 마감가:
$2.165
열려 있는:
$2.1101
하루 거래량:
23,708
Relative Volume:
0.30
시가총액:
$11.19M
수익:
$468.00K
순이익/손실:
$-10.34M
주가수익비율:
-0.3064
EPS:
-7.05
순현금흐름:
$-8.94M
1주 성능:
+9.64%
1개월 성능:
-29.18%
6개월 성능:
-5.26%
1년 성능:
-58.46%
1일 변동 폭
$2.09
$2.2456
1주일 범위
$1.95
$2.2456
52주 변동 폭
$1.625
$5.69
Biocardia Inc Stock (BCDA) Company Profile
명칭
Biocardia Inc
전화
650-226-0123
주소
320 SOQUEL WAY, SUNNYVALE, CA
BCDA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.43 | 372.90M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
11.50 | 190.93M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.76 | 131.34M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1601 | 350.74M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.4197 | 636.80M | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-04-16 | 다운그레이드 | Dawson James | Buy → Neutral |
Biocardia Inc 주식(BCDA)의 최신 뉴스
Biocardia CEO Peter Altman acquires $221 in company stock - Investing.com
BioCardia to Participate in Fireside Chat at A.G.P. Virtual Heal - GuruFocus
BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 - The Manila Times
BioCardia Reveals Latest Progress on Revolutionary Cell Therapy for Heart Failure at Major Healthcare Conference - Stock Titan
BioCardia, Inc. (NASDAQ:BCDA) Q1 2025 Earnings Call Transcript - Insider Monkey
BioCardia’s Earnings Call: Progress Amid Financial Strain - TipRanks
BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ... - Yahoo Finance
BioCardia Reports Positive Q1 2025 Progress - TipRanks
Earnings call transcript: BioCardia’s Q1 2025 results show clinical progress - Investing.com
BioCardia Reports First Quarter 2025 Business Highlights and Financial Results - The Manila Times
BioCardia Reports Groundbreaking Heart Failure Trial Results: 82% Reduction in Angina Episodes - Stock Titan
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 - The Manila Times
BioCardia to Host Q1 2025 Corporate Update and Financial Results - GuruFocus
Insider Buying Surges in May. Especially These 5 Stocks - 24/7 Wall St.
BioCardia (BCDA) Expands Enrollment for Phase 3 CardiAMP HF II T - GuruFocus
BioCardia Advances Phase 3 CardiAMP HF II Trial - TipRanks
BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study - The Manila Times
First subject enrolled in BioCardia’s Phase III heart failure therapy trial - Yahoo
Form 8-KCurrent report - ADVFN
BioCardia Advances Cardiac Cell Therapy With Start Of Phase 3 CardiAMP HF II Trial - Nasdaq
BioCardia (BCDA) Moves Forward With Phase III CardiAMP HF II Tri - GuruFocus
BioCardia (BCDA) Moves Forward With Phase III CardiAMP HF II Trial | BCDA Stock News - GuruFocus
BioCardia Enrolls First Patient in Phase III Trial - TipRanks
BioCardia's Revolutionary Cell Therapy Enters Final Testing Phase for Heart Failure TreatmentKey Trial Details - Stock Titan
BioCardia (BCDA) Gains Attention Amid Surge in Search Activity | - GuruFocus
Biocardia CFO David McClung buys $24,999 in company stock By Investing.com - Investing.com Australia
Biocardia CFO David McClung buys $24,999 in company stock - Investing.com
BioCardia Executives Increase Their Stakes in the Company - TradingView
Biocardia CEO Peter Altman acquires $1,488 in stock - MSN
Beating Heart Patch Market Detailed In New Research Report 2025 | - openPR.com
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results - ADVFN
Biocardia CEO Peter Altman buys $214 in company stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman buys $214 in company stock - Investing.com Australia
DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure - Yahoo
BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed By Investing.com - Investing.com South Africa
BioCardia (BCDA) Receives Positive DSMB Recommendation for Cardi - GuruFocus
Biocardia Announces Positive Dsmb Review Of Cardiallo Allogeneic Cell Therapy For Heart Failure Phase 1/2 Clinical Trial - marketscreener.com
BioCardia’s CardiALLO Trial Advances After Safety Review - TipRanks
BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed - Investing.com
BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic - GuruFocus
BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial - The Manila Times
Major Safety Milestone: Revolutionary Heart Failure Cell Therapy Advances to Next Phase - Stock Titan
Biocardia Inc (BCDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Biocardia Inc 주식 (BCDA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Altman Peter | President and CEO |
May 20 '25 |
Buy |
2.08 |
1,600 |
3,328 |
140,966 |
| Altman Peter | President and CEO |
May 22 '25 |
Buy |
1.89 |
700 |
1,323 |
141,666 |
| Altman Peter | President and CEO |
May 16 '25 |
Buy |
2.43 |
300 |
730 |
139,366 |
| Altman Peter | President and CEO |
May 14 '25 |
Buy |
2.99 |
100 |
299 |
139,066 |
| KRASNO RICHARD M | Director |
Apr 23 '25 |
Buy |
1.91 |
13,123 |
24,999 |
16,268 |
| McClung David | Chief Financial Officer |
Apr 23 '25 |
Buy |
1.91 |
13,123 |
24,999 |
43,131 |
| Facteau Bill | Director |
Apr 23 '25 |
Buy |
1.91 |
13,123 |
24,999 |
13,123 |
| Blank Andrew Scott | Director |
Apr 23 '25 |
Buy |
1.91 |
131,233 |
249,999 |
265,957 |
| STERTZER SIMON H | Director |
Apr 23 '25 |
Buy |
1.91 |
104,986 |
199,998 |
120,365 |
| Altman Peter | President and CEO |
Apr 23 '25 |
Buy |
1.91 |
26,246 |
49,999 |
138,966 |
1.89%
3.74%
자본화:
|
볼륨(24시간):